Literature DB >> 22104683

Is completion lobectomy merited for unanticipated nodal metastases after radical segmentectomy for cT1 N0 M0/pN1-2 non-small cell lung cancer?

Hiroaki Nomori1, Takeshi Mori, Yotaro Izumi, Mitsutomo Kohno, Kentaro Yoshimoto, Makoto Suzuki.   

Abstract

OBJECTIVE: To examine the role of radical segmentectomy, defined as a segmentectomy with extensive hilar/mediastinal lymph node dissection and a sufficient surgical margin, for local control in cT1 N0 M0/pN1-2 non-small cell lung cancer (NSCLC), we examined the following: (1) whether metastases were observed in specimens additionally resected by completion lobectomy undertaken after segmentectomy because of pN1-2 disease and (2) prognostic outcome in patients whose operations were completed with segmentectomy regardless of pN1-2.
METHODS: Of 275 patients with cT1 N0 M0 NSCLC who were scheduled to undergo radical segmentectomy, 15 (6%) had a diagnosis of pN1 or N2 disease. Of these patients, 10 were additionally treated with completion lobectomy, whereas the operations of the remaining 5 were completed with segmentectomy.
RESULTS: None of the 10 patients who underwent completion lobectomy showed residual metastases in the specimens additionally resected by completion lobectomy. Two of the 5 patients whose operations were completed with segmentectomy, regardless of N1 or N2 disease, had tumor recurrence, but their first recurrence was not local.
CONCLUSIONS: Radical segmentectomy, with extensive hilar/mediastinal lymph node dissection and a sufficient surgical margin, may play a role in local control in patients with cT1 N0 M0/pN1-2 NSCLC. Copyright Â
© 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22104683     DOI: 10.1016/j.jtcvs.2011.10.045

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  16 in total

1.  Is it safe to perform completion lobectomy after diagnostic wedge resection using video-assisted thoracoscopic surgery?

Authors:  Bo Laksáfoss Holbek; René Horsleben Petersen; Henrik Jessen Hansen
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-02-25

2.  Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer.

Authors:  Norifumi Tsubokawa; Yasuhiro Tsutani; Yoshihiro Miyata; Yoshinori Handa; Keizo Misumi; Hideaki Hanaki; Eisuke Hida; Morihito Okada
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

Review 3.  Anatomical thoracoscopic segmentectomy for lung cancer.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-05-03

Review 4.  Therapeutic strategy for small-sized lung cancer.

Authors:  Hisashi Iwata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-06-14

Review 5.  Lymph node dissection during sublobar resection: why, when and how?

Authors:  Pascal-Alexandre Thomas
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

6.  Clinical outcomes and changes in lung function after segmentectomy versus lobectomy for lung cancer cases.

Authors:  Bo Deng; Stephen D Cassivi; Mariza de Andrade; Francis C Nichols; Victor F Trastek; Yi Wang; Jason A Wampfler; Shawn M Stoddard; Dennis A Wigle; Robert K Shen; Mark S Allen; Claude Deschamps; Ping Yang
Journal:  J Thorac Cardiovasc Surg       Date:  2014-03-20       Impact factor: 5.209

Review 7.  Segmentectomy for c-T1N0M0 non-small cell lung cancer.

Authors:  Hiroaki Nomori
Journal:  Surg Today       Date:  2013-06-29       Impact factor: 2.549

8.  Node-Positive Segmentectomy for Non-Small-Cell Lung Cancer: Risk Factors and Outcomes.

Authors:  Waseem Lutfi; Matthew J Schuchert; Rajeev Dhupar; Chigozirim Ekeke; Inderpal S Sarkaria; Neil A Christie; James D Luketich; Olugbenga T Okusanya
Journal:  Clin Lung Cancer       Date:  2019-04-01       Impact factor: 4.785

9.  Appropriate lymphadenectomy significantly reduced recurrence after segmentectomy for patients with non-small cell lung cancer.

Authors:  Qingyuan Huang; Rui Wang; Chang Gu; Changqing Pan; Heng Zhao; Qingquan Luo; Yiyang Wang; Jiajie Zheng; Haiquan Chen
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

10.  Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer.

Authors:  Hiroaki Komatsu; Shinjiro Mizuguchi; Nobuhiro Izumi; Kyukwang Chung; Shoji Hanada; Hidetoshi Inoue; Shigefumi Suehiro; Noritoshi Nishiyama
Journal:  World J Surg Oncol       Date:  2013-12-06       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.